Orpyx®

Orpyx® is a leading digital therapeutics company committed to extending healthspan for people living with diabetes through personalized remote care. Their flagship product, the Orpyx® Sensory Insoles, is transforming diabetes care by helping prevent diabetic foot ulcers, a major complication that can lead to amputation. This Canadian-based company, founded in 2010, boasts a dedicated remote patient monitoring team comprised of credentialed providers and nurses. They utilize advanced data science methodologies to provide personalized support and triaged clinical escalation. With a whole-person approach, Orpyx empowers people to take control of their health, prevent debilitating complications, and extend their healthspan. In their latest funding round, Orpyx secured a $7.60M Series A investment on 08 July 2020. Key investors in this round include Anges Québec, Aphelion Capital, InterGen Capital, Thin Air Labs, Viewpoint, ICM Asset Management, Paddock Capital, Relentless Pursuit Partners, and Picante Capital. This impressive support from a diverse group of investors signifies the recognition of Orpyx's potential to make a significant impact in the health care industry. In summary, Orpyx is positioned at the forefront of utilizing digital therapeutics to enhance the lives of individuals with diabetes. Their innovative approach and recent substantial investment demonstrate their potential for long-term success in this crucial health care sector.